These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8970044)

  • 1. Diagnostic bias in clinical decision making: an example of L-tryptophan and the diagnosis of eosinophilia-myalgia syndrome.
    Wagner KR; Elmore JG; Horwitz RI
    J Rheumatol; 1996 Dec; 23(12):2079-85. PubMed ID: 8970044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bias or biology: evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome.
    Horwitz RI; Daniels SR
    J Rheumatol Suppl; 1996 Oct; 46():60-72. PubMed ID: 8895182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases.
    Sullivan EA; Staehling N; Philen RM
    J Rheumatol; 1996 Oct; 23(10):1784-7. PubMed ID: 8895159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of L-tryptophan and eosinophilia-myalgia syndrome.
    Roufs JB
    J Am Diet Assoc; 1992 Jul; 92(7):844-50. PubMed ID: 1624654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome.
    Kilbourne EM; Philen RM; Kamb ML; Falk H
    J Rheumatol Suppl; 1996 Oct; 46():81-8; discussion 89-91. PubMed ID: 8895184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York.
    Back EE; Henning KJ; Kallenbach LR; Brix KA; Gunn RA; Melius JM
    J Rheumatol; 1993 Apr; 20(4):666-72. PubMed ID: 8496862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Centers for Disease Control and Prevention criteria for the eosinophilia-myalgia syndrome in a geographically defined population.
    Spitzer WO; Haggerty JL; Berkson L; Davis W; Palmer W; Tamblyn R; Laprise R; Mulder LJ
    J Rheumatol Suppl; 1996 Oct; 46():73-9; discussion 79-80. PubMed ID: 8895183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
    Shapiro S
    J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of the eosinophilia-myalgia syndrome].
    Ishikawa A; Akahosi T; Okada J; Kondo H; Kasiwazaki S
    Ryumachi; 1992 Aug; 32(4):327-30; discussion 330-2. PubMed ID: 1411794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibromyalgia, psychiatric disorders, and assessment of the longterm outcome of eosinophilia-myalgia syndrome.
    Hudson JI; Pope HG; Carter WP; Daniels SR
    J Rheumatol Suppl; 1996 Oct; 46():37-42; discussion 42-3. PubMed ID: 8895180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Eosinophilia-myalgia syndrome].
    Kotake S; Kashiwazaki S
    Nihon Rinsho; 1992 Jul; 50(7):1650-5. PubMed ID: 1404896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A diagnostic algorithm for distinguishing the eosinophilia-myalgia syndrome from fibromyalgia and chronic myofascial pain.
    Taylor RM; Gabriel SE; O'Fallon WM; Bowles CA; Duffy J
    J Rheumatol Suppl; 1996 Oct; 46():13-8. PubMed ID: 8895177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models of the eosinophilia-myalgia syndrome.
    Clauw DJ
    J Rheumatol Suppl; 1996 Oct; 46():93-7; discussion 92, 97-8. PubMed ID: 8895185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Eosinophilia-myalgia syndrome after L-tryptophan intake].
    Zillikens D; Bammel A; Lurz C; Elsner P; Burg G
    Hautarzt; 1991 Mar; 42(3):154-7. PubMed ID: 2055764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina.
    Sullivan EA; Kamb ML; Jones JL; Meyer P; Philen RM; Falk H; Sinks T
    Arch Intern Med; 1996 May; 156(9):973-9. PubMed ID: 8624177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan.
    Michelson D; Page SW; Casey R; Trucksess MW; Love LA; Milstien S; Wilson C; Massaquoi SG; Crofford LJ; Hallett M
    J Rheumatol; 1994 Dec; 21(12):2261-5. PubMed ID: 7699627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced severity of eosinophilia-myalgia syndrome associated with the consumption of vitamin-containing supplements before illness.
    Hatch DL; Goldman LR
    Arch Intern Med; 1993 Oct; 153(20):2368-73. PubMed ID: 8215741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Polyneuropathy and fasciitis in eosinophilia-myalgia syndrome].
    Hetzel W; Dangel P; Molitor H
    Fortschr Neurol Psychiatr; 1991 Oct; 59(10):425-31. PubMed ID: 1662183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Criteria for the definition of the eosinophilia-myalgia syndrome.
    Hertzman PA
    J Rheumatol Suppl; 1996 Oct; 46():7-12. PubMed ID: 8895176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contaminants in L-tryptophan associated with eosinophilia myalgia syndrome.
    Hill RH; Caudill SP; Philen RM; Bailey SL; Flanders WD; Driskell WJ; Kamb ML; Needham LL; Sampson EJ
    Arch Environ Contam Toxicol; 1993 Jul; 25(1):134-42. PubMed ID: 8346973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.